Evidence map›Paper›PMID 32562159›Full record

Observational studyDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2020

The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.

Ensieh Vahedi, Mostafa Ghanei, Ali Ghazvini, Hossein Azadi, Morteza Izadi, Yunes Panahi, Saeid Fathi, Mahmood Salesi, Seyed Hassan Saadat, Amir Hossein Ghazale and 8 more

Open access · bronzeAbstract readComparative StudyObservational Study
In one paragraph

Observational study in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 4 pooled it
0.4field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Is there any potential management against COVID-19? A systematic review and meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020
    Pooled it
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Ensieh VahediChemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mostafa GhaneiChemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. mghaneister@gmail.com.
Ali GhazviniChemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Hossein AzadiChemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Morteza IzadiHealth Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Yunes PanahiFaculty of pharmacy, pharmacotherapy department, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Saeid FathiUniversity of Tehran, Tehran, Iran.
Mahmood SalesiChemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Seyed Hassan SaadatBehavioral sciences research center, Lifestyle institute, Baqiatallah University of Medical Sciences, Tehran, Iran.
Amir Hossein GhazaleStudent Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.
Mohammad RezapourStudent Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.
Abolfazl MozafariDepartment of Medical Science, Qom Branch, Islamic Azad University, Qom, Iran.
Nahid ZandDepartment of Internal Medicine, Qom university of medical sciences, Qom, Iran.
Mohammadreza Raesi ParsaeiStudent Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.
Mohammad Hossein RanjkeshStudent Research committee, Baqiyatallah University of medical Sciences, Tehran, Iran.
Ramezan JafariDepartment of Radiology and Chemical Injury Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Fatemeh MovaseghiDepartment of Medical Science, Qom Branch, Islamic Azad University, Qom, Iran.
Enayat DarabiSchool of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Baqiyatallah University of Medical Sciences · IRQom Islamic Azad University · IRQom University of Medical Science and Health Services · IRTehran University of Medical Sciences · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is no identified pharmacological therapy for COVID-19 patients, where potential therapeutic strategies are underway to determine effective therapy under such unprecedented pandemic. Therefore, combination therapies may have the potential of alleviating the patient's outcome. This study aimed at comparing the efficacy of two different combination regimens in improving outcomes of patients infected by novel coronavirus (COVID-19).

methodsThis is a single centered, retrospective, observational study of 60 laboratory-confirmed COVID-19 positive inpatients (≥18 years old) at two wards of the Baqiyatallah Hospital, Tehran, Iran. Patient's data including clinical and laboratory parameters were recorded. According to the drug regimen, the patients were divided into two groups; group I who received regimen I consisting azithromycin, prednisolone, naproxen, and lopinavir/ritonavir and group II who received regimen II including meropenem, levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir.

resultsThe oxygen saturation (SpO2) and temperature were positively changed in patients receiving regimen I compared to regimen II (P = 0.013 and P = 0.012, respectively). The serum level of C-reactive protein (CRP) changed positively in group I (P < 0.001). Although there was a significant difference in platelets between both groups (75.44 vs 51.62, P < 0.001), their change did not clinically differ between two groups. The findings indicated a significant difference of the average length of stay in hospitals (ALOS) between two groups, where the patients under regimen I showed a shorter ALOS (6.97 vs 9.93, P = 0.001).

conclusionThis study revealed the beneficial effect of the short-term use of low-dose prednisolone in combination with azithromycin, naproxen and lopinavir/ritonavir (regimen I), in decreasing ALOS compared to regimen II. Since there is still lack of evidence for safety of this regimen, further investigation in our ongoing follow-up to deal with COVID-19 pneumonia is underway. Graphical abstract.

Indexed as

COVID-19 Drug TreatmentAdultAgedAzithromycinCOVID-19Drug CombinationsDrug Therapy, CombinationFemaleHospitalizationHumansHydroxychloroquineIranLength of StayLevofloxacinLopinavirMaleAzithromycinDrug CombinationsHydroxychloroquineLevofloxacinLopinavirlopinavir-ritonavir drug combinationMeropenemNaproxenOseltamivirPrednisoloneRitonavirVancomycinCombination therapyCoronavirus disease 2019Length of stay in hospitals (ALOS)

Identifiers

PMID32562159
PMCPMC7303568
OpenAlexW3036520021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.